Abstract
Renin-angiotensin-aldosterone system inhibitors (RAASi) have been repeatedly demonstrated to significantly slow progression of CKD in randomized controlled trials conducted in adults ([1][1],[2][2]). The mechanisms by which RAASi slow progression of CKD include the reduction of proteinuria and
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical journal of the American Society of Nephrology : CJASN
Paper Title
Journal
Date
